NCT06368921View on ClinicalTrials.gov

A Study of Recombinant Oncolytic Virus M1(VRT106) in Patients With Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 19, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

December 31, 2025

Conditions
Solid Tumor
Interventions
BIOLOGICAL

VRT106

intratumoral injection

Trial Locations (3)

Unknown

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

RECRUITING

Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou

RECRUITING

Affiliated Cancer Hospital of Shandong First Medical University, Jinan

Sponsors
All Listed Sponsors
lead

Guangzhou Virotech Pharmaceutical Co., Ltd.

INDUSTRY

NCT06368921 - A Study of Recombinant Oncolytic Virus M1(VRT106) in Patients With Solid Tumors | Biotech Hunter | Biotech Hunter